Linzess (linaclotide) carries a retail price around $282 for a 30-day supply, and there is no generic version available yet. A generic has received tentative FDA approval but cannot launch until a key patent expires on August 30, 2026. Until then, your options for spending less fall into three categories: over-the-counter alternatives, other prescription medications, and savings programs that reduce what you pay for Linzess itself.
When the Generic Arrives
The FDA has already reviewed and tentatively approved a generic version of linaclotide capsules, confirming it is bioequivalent to brand-name Linzess. The holdup is a patent that doesn’t expire until August 30, 2026. After that date, the generic can receive final approval and reach pharmacies. Generic drugs typically cost 30% to 80% less than brand-name versions, so this should significantly reduce the price once it’s available.
Over-the-Counter Options to Try First
Many insurance plans actually require you to try cheaper options before they’ll cover Linzess. These step-therapy requirements exist because several inexpensive, widely available products work well for many people with constipation. A Kaiser Permanente formulary document lays out a common sequence insurers follow: fiber supplements like psyllium (Metamucil) or methylcellulose (Citrucel), then osmotic laxatives like polyethylene glycol (MiraLAX) or lactulose, then stimulant laxatives like senna or bisacodyl.
All of these cost under $15 to $25 per month at most pharmacies. They work through different mechanisms than Linzess. MiraLAX draws water into the colon to soften stool. Fiber supplements add bulk that helps move things along. Stimulant laxatives trigger the muscles in your intestinal wall to contract. None of these directly reduce the abdominal pain associated with IBS-C the way Linzess does, which is a meaningful distinction if pain is your primary symptom. But for straightforward chronic constipation without significant pain, they’re a reasonable and far cheaper starting point.
Prescription Alternatives and Their Costs
If OTC options haven’t worked, several prescription medications treat the same conditions as Linzess. None are cheap, but some may cost less depending on your insurance plan’s formulary.
Amitiza (Lubiprostone)
Amitiza is approved for IBS with constipation, chronic idiopathic constipation, and opioid-induced constipation. Its retail price runs around $403 for a 30-day supply (60 capsules at the 8 mcg strength), which is more expensive than Linzess at retail. However, your insurance may place it on a lower formulary tier, meaning your copay could actually be less. Amitiza works differently from Linzess. It activates chloride channels on the lining of your intestine, which pulls fluid into the gut to soften stool and stimulate movement. It does not target pain signaling the way Linzess does.
Trulance (Plecanatide)
Trulance is the closest relative to Linzess. Both activate the same receptor on the cells lining your intestine, triggering fluid secretion, reducing inflammation, and dampening pain signals from the gut. The key difference is that Trulance is most active in the acidic environment of the small intestine, while Linzess works equally throughout the entire digestive tract. Trulance’s retail price is roughly $617 for 30 tablets, making it more expensive out of pocket. But again, insurance copays vary, and some plans cover Trulance more favorably. It’s approved for chronic idiopathic constipation and IBS with constipation.
Ibsrela (Tenapanor)
Ibsrela takes a completely different approach. It blocks sodium absorption in the gut, which keeps more water in the intestinal space and speeds up transit. It also tightens the junctions between cells in the intestinal lining (reducing permeability, sometimes called “leaky gut”) and works on pain receptors. It’s approved specifically for IBS with constipation, not for chronic constipation alone. Retail pricing varies, so checking with your pharmacy or insurance is worthwhile.
Motegrity (Prucalopride)
Motegrity shows up in insurer step-therapy lists for chronic constipation. It works by stimulating serotonin receptors in the gut wall, which increases the coordinated muscle contractions that push stool forward. It’s approved for chronic idiopathic constipation but not IBS-C, so it won’t help with IBS-related pain.
How Insurance Affects Your Real Cost
The retail prices above rarely reflect what you’d actually pay with insurance, but coverage for these medications is often restrictive. Linzess is frequently classified as non-formulary or placed on a high tier, meaning your plan may not cover it at all unless you’ve documented that cheaper treatments failed. Kaiser Permanente’s criteria are representative of what many insurers require: for IBS-C, you typically need to have tried and failed a fiber supplement, MiraLAX, lubiprostone, and Trulance before Linzess gets approved. For chronic constipation, the list is even longer, adding stimulant laxatives and Motegrity.
This means your path to the cheapest effective option often involves working through less expensive treatments systematically, keeping records of what you tried and why it didn’t work. If your doctor documents at least four weeks on each failed therapy, the prior authorization process for Linzess or its alternatives becomes much smoother.
Savings Programs for Linzess
If Linzess is the medication that works for you, the manufacturer offers a savings card that can reduce your cost by up to $8 per fill off the retail price. That’s a modest discount, but it applies whether or not you have insurance. Eligibility requirements exist, and the savings amount can vary, so checking the current terms on the Linzess website or asking your pharmacist is the most reliable way to confirm what you’d save.
Beyond the manufacturer card, GoodRx and similar discount platforms sometimes offer coupons that bring the cash price below the listed retail. These won’t stack with insurance but can help if you’re paying out of pocket. Pharmacy prices also vary, so calling two or three pharmacies (including Costco, which doesn’t require a membership for prescriptions) can reveal meaningful price differences for the same medication.
Choosing Based on Your Diagnosis
Which alternative makes the most sense depends partly on what you’re treating. If you have chronic constipation without significant abdominal pain, OTC osmotic laxatives like MiraLAX are the obvious first step. They cost a fraction of any prescription option and work well for many people.
If you have IBS-C, where pain and bloating are central to the problem, the calculus changes. Linzess, Trulance, and Ibsrela all address both the constipation and the pain component through different pathways. Amitiza and MiraLAX primarily help with stool consistency and frequency but don’t target visceral pain directly. So switching to a cheaper option that only treats constipation may leave your worst symptom unmanaged.
The most practical strategy for most people is to start with OTC options, document the results over four to six weeks, and use that history to support a prior authorization for a prescription medication if needed. With a generic version of Linzess potentially arriving in late 2026, the pricing landscape for this class of medication could shift substantially within the next year or so.